Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 152 DLBCL: DA-EPOCH-R induction followed by nivolumab consolidation in newly diagnosed double-hit/triple-hit high-grade B-cell lymphoma
NL-OMON59517Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, rituximab, etoposide, prednisone, vincristine and 2 more in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) and diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: 12-month disease-free survival. Started Jul 2018; status: active, not recruiting.
02
Drugs
03
Conditions
high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON59517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59517.